Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

maintenance dose), the ICER was £11,660 per quality-adjusted life year (QALY) gained. • For the core clinical cohort (excluding prior stroke or transient ischaemic attack and those weighing less than 60 kg, or aged 75 years or older), the ICER was £11,796 per QALY gained. • For the unstable angina or NSTEMI licensed population (excluding patients with prior stroke or transient ischaemic attack and including patients who are now recommended to be treated with a 5 mg dose), the ICER was £15,452 per QALY gained. • For the STEMI licensed population (excluding patients with prior stroke or transient ischaemic attack and including patients who were recommended to be treated with a 5 mg dose), the ICER was £6,987 per QALY gained. • For the acute coronary syndromes licensed population with diabetes (excluding patients with prior stroke or transient ischaemic attack and including patients who were recommended to be treated with a 5 mg dose) the ICER was £4,675 per QALY gained. 4.2.5 The manufacturer carried out a series of one-way deterministic sensitivity analyses on the core clinical cohort population (excluding prior stroke or transient ischaemic attack and those 75 years or older or weighing less than 60 kg). The following
